| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
25,710,000 |
| Market
Cap: |
12.98(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,254,871 |
| 52
Week Range: |
$267.56 - $602.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 24.7 |
| Insider 3/6 Months : 25.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
165,683 |
165,683 |
165,683 |
| Total Buy Value |
$0 |
$61,921,024 |
$61,921,024 |
$61,921,024 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
123,436 |
372,078 |
490,415 |
796,841 |
| Total Sell Value |
$65,479,714 |
$156,868,414 |
$198,281,453 |
$274,818,386 |
| Total People Sold |
8 |
8 |
10 |
11 |
| Total Sell Transactions |
13 |
22 |
40 |
66 |
| End Date |
2025-10-24 |
2025-07-23 |
2025-01-22 |
2024-01-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Taub Rebecca |
Director |
– • – |
2026-01-20 |
4 |
S |
$490.77 |
$1,098,343 |
D/D |
(2,238) |
453,351 |
|
- |
|
| Kelley Shannon T |
General Counsel |
• – – |
2026-01-20 |
4 |
AS |
$490.77 |
$344,173 |
D/D |
(692) |
8,481 |
|
- |
|
| Thakkar Rita |
Chief Accounting Officer |
• – – |
2026-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,398 |
2,398 |
|
- |
|
| Taub Rebecca |
Director |
– • – |
2026-01-09 |
4 |
AS |
$545.79 |
$132,080 |
D/D |
(240) |
455,589 |
|
-2% |
|
| Taub Rebecca |
Director |
– • – |
2026-01-09 |
4 |
OE |
$15.80 |
$3,792 |
D/D |
240 |
455,829 |
|
- |
|
| Taub Rebecca |
Director |
– • – |
2026-01-09 |
4 |
AS |
$512.02 |
$9,617,312 |
D/D |
(18,410) |
455,589 |
|
-2% |
|
| Taub Rebecca |
Director |
– • – |
2026-01-09 |
4 |
OE |
$15.80 |
$290,878 |
D/D |
18,410 |
473,999 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2026-01-09 |
4 |
AS |
$511.98 |
$12,808,957 |
D/D |
(24,520) |
187,164 |
|
-2% |
|
| Friedman Paul A |
Director |
– • – |
2026-01-09 |
4 |
OE |
$15.80 |
$387,416 |
D/D |
24,520 |
211,684 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2026-01-09 |
4 |
AS |
$551.24 |
$154,348 |
D/D |
(280) |
187,164 |
|
-2% |
|
| Friedman Paul A |
Director |
– • – |
2026-01-09 |
4 |
OE |
$15.80 |
$4,424 |
D/D |
280 |
187,444 |
|
- |
|
| Taub Rebecca |
Director |
– • – |
2025-12-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,455 |
455,589 |
|
- |
|
| Taub Rebecca |
Director |
– • – |
2025-12-10 |
4 |
AS |
$547.76 |
$10,297,573 |
D/D |
(18,650) |
461,044 |
|
-9% |
|
| Taub Rebecca |
Director |
– • – |
2025-12-10 |
4 |
OE |
$15.80 |
$294,670 |
D/D |
18,650 |
479,694 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2025-12-10 |
4 |
AS |
$547.75 |
$13,694,158 |
D/D |
(24,800) |
187,164 |
|
-9% |
|
| Friedman Paul A |
Director |
– • – |
2025-12-10 |
4 |
OE |
$15.80 |
$391,840 |
D/D |
24,800 |
211,964 |
|
- |
|
| Sibold William John |
President and CEO |
• • – |
2025-12-04 |
4 |
S |
$575.34 |
$1,380,816 |
D/D |
(2,400) |
150,074 |
|
14% |
|
| Sibold William John |
President and CEO |
• • – |
2025-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
152,474 |
|
- |
|
| Dier Mardi |
EVP and CFO |
• – – |
2025-12-02 |
4 |
AS |
$570.39 |
$2,413,416 |
D/D |
(4,173) |
10,440 |
|
-12% |
|
| Dier Mardi |
EVP and CFO |
• – – |
2025-12-02 |
4 |
OE |
$251.63 |
$1,050,052 |
D/D |
4,173 |
14,613 |
|
- |
|
| Huntsman Carole |
Chief Commercial Officer |
• – – |
2025-11-21 |
4 |
AS |
$547.27 |
$1,082,986 |
D/D |
(1,958) |
10,032 |
|
-8% |
|
| Levy Richard S |
Director |
– • – |
2025-11-13 |
4 |
AS |
$514.67 |
$4,428,198 |
D/D |
(8,500) |
21,197 |
|
-3% |
|
| Levy Richard S |
Director |
– • – |
2025-11-13 |
4 |
OE |
$7.36 |
$117,160 |
D/D |
8,500 |
29,697 |
|
- |
|
| Bate Kenneth |
Director |
– • – |
2025-11-05 |
4 |
S |
$480.24 |
$8,027,354 |
D/D |
(16,575) |
2,627 |
|
-6% |
|
| Bate Kenneth |
Director |
– • – |
2025-11-05 |
4 |
OE |
$9.45 |
$3,399,036 |
D/D |
16,575 |
19,202 |
|
- |
|
253 Records found
|
|
Page 1 of 11 |
|
|
3.27 (0.65%) 
